| FVLKX | VMVAX | FVLKX / VMVAX | |
| Total Expense Ratio | 0.73 | 0.07 | 1,043% |
| Annual Report Gross Expense Ratio | 0.73 | 0.07 | 1,043% |
| Fund Existence | 18 years | 14 years | - |
| Gain YTD | 5.495 | 4.224 | 130% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 3000 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 8.43B | 33.2B | 25% |
| Annual Yield % from dividends | 1.33 | 2.10 | 63% |
| Returns for 1 year | 8.13 | 13.84 | 59% |
| Returns for 3 years | 12.26 | 30.76 | 40% |
| Returns for 5 years | 21.65 | 51.40 | 42% |
| Returns for 10 years | 80.51 | 142.26 | 57% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| TISBX | 27.60 | 0.19 | +0.69% |
| Nuveen Small Cap Blend Idx R6 | |||
| CVCFX | 16.33 | 0.05 | +0.31% |
| Victory Pioneer Disciplined Value C | |||
| VFWPX | 159.43 | 0.42 | +0.26% |
| Vanguard FTSE All-Wld ex-US Idx Ins Plus | |||
| BCEMX | 30.97 | 0.02 | +0.06% |
| Boston Common ESG Impact Em Mkts | |||
| GSURX | 62.70 | -0.47 | -0.74% |
| Goldman Sachs US Equity Insights R | |||